This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody & ADC Summit At ChinaBio
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026
Book Now
Menu
Book
Key Sessions
Shan Jiang, PhD
Advancing ADCs to the Clinic: Case Study of Innovations in ADC Technology and Development
Hansoh Pharma
Jan van de Winkel, PhD
Next-generation Antibody Therapeutics for Cancer
Genmab
Tomoyuki Igawa, PhD
Chugai’s Drug Discovery Driven by Antibody Engineering Technologies
Chugai Pharmaceutical Co., Ltd.
keyboard_arrow_right

Day 1 - CT (China Time, GMT+08:00)

keyboard_arrow_leftSearch & Filter
search
Day 1 - CT (China Time, GMT+08:00)
search
Showing 1 of 1 Streams
08:00 - 08:40
Registration and Morning Coffee
08:40 - 08:45
Chairperson’s Remarks
08:45 - 09:25
Next-generation Antibody Therapeutics for Cancer
  • Jan van de Winkel, PhD - President and CEO, Genmab
09:25 - 10:05
Chugai’s Drug Discovery Driven by Antibody Engineering Technologies
  • Tomoyuki Igawa, PhD - Head of Research, Chugai Pharmaceutical Co., Ltd.
Showing 1 of 1 Streams
10:05 - 10:40
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 1 of 1 Streams
10:40 - 11:20
Advancing ADCs to the Clinic: Case Study of Innovations in ADC Technology and Development
  • Shan Jiang, PhD - Chief Technology Officer, Hansoh Pharma
11:20 - 12:00
Panel Discussion: East Meets West: China's Market Dynamics and Global Investment Trends Shaping the Future of ADC Therapies
  • Cong Xu, MD, PhD - Managing Director, Lilly Asia Ventures
12:00 - 12:30
Sponsored Scientific Briefing
Showing 1 of 1 Streams
12:30 - 13:40
Networking Luncheon
Showing 2 of 2 Streams
13:40 - 13:45
Chairperson’s Remarks
13:45 - 14:15
Combining Bispecific T-cell Engagers and Costimulatory Agonist Antibodies: An "Off-the-Shelf" Approach for Cancer Therapy
  • Sara Colombetti, PhD - Head of Translational Pharmacology, Roche Oncology pRED, F. Hoffmann-La Roche AG
14:15 - 14:45
Folding-mediated Secretion of Pure Bispecific Antibodies
  • Adam Zwolak, PhD - Director, Biologics Discovery, Johnson & Johnson Innovative Medicine
14:45 - 15:15
Sponsored Scientific Briefing
13:40 - 13:45
Chairperson’s Remarks
13:45 - 14:15
New ADC Payload: Antibody Drug Conjugates with a Novel Protein Translation Inhibitor Payload
  • Tara Arvedson, PhD - Chief Scientific Officer, Hexagon Bio
14:15 - 14:45
Duality Next-generation Novel Payload Technologies
  • Haiqing Hua, PhD - Senior Vice President and Head of Drug Discovery, DualityBio
14:45 - 15:15
Sponsored Scientific Briefing
Showing 1 of 1 Streams
15:15 - 15:45
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 2 of 2 Streams
15:45 - 16:15
The MultipleBody and AccuBody Enabled Development of Multi-Specific Biotherapeutics for Unmet Medical Needs
  • Yongliang Fang, PhD - COO, Doer Biologics
16:15 - 16:45
Human Antibody Discovery and Engineering: The Adimab Way
  • Aaron Sato, PhD - Chief Strategy Officer, Adimab
16:45 - 17:15
Late Breaking Presentation
15:45 - 16:15
Harnessing the Therapeutic Promise of Multi-payload ADCs
  • Jerome Boyd-Kirkup, PhD - Chief Scientific Officer and Co-Founder, Callio Therapeutics
16:15 - 16:45
Highly Efficacious and Tolerated Multi-payload ADCs Assembled in One step without Any Antibody Engineering
  • Filippo Mulinacci, PhD - Chief Business Officer, Araris Biotech
16:45 - 17:15
Late Breaking Presentation
Showing 1 of 1 Streams
17:15 - 18:15
Networking Reception
NextDay 2
Filter
Streams
Formats
Choose Day